HomePRE • NASDAQ
add
Prenetics Global Ltd
Previous close
$4.61
Day range
$4.42 - $4.42
Year range
$2.85 - $7.84
Market cap
54.00M USD
Avg Volume
11.72K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Revenue | 5.94M | 4.32% |
Operating expense | 14.38M | 0.52% |
Net income | -10.72M | 50.83% |
Net profit margin | -180.46 | 52.87% |
Earnings per share | — | — |
EBITDA | -9.51M | 13.59% |
Effective tax rate | 0.79% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 63.89M | -67.46% |
Total assets | 233.31M | -16.93% |
Total liabilities | 42.30M | -30.22% |
Total equity | 191.00M | — |
Shares outstanding | 12.22M | — |
Price to book | 0.30 | — |
Return on assets | -11.12% | — |
Return on capital | -13.33% | — |
Cash Flow
Net change in cash
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Net income | -10.72M | 50.83% |
Cash from operations | — | — |
Cash from investing | — | — |
Cash from financing | — | — |
Net change in cash | — | — |
Free cash flow | — | — |
About
Prenetics is a health sciences company headquartered in Hong Kong with a significant presence in the United States. It is best known for its innovations in consumer and clinical health, focusing on early detection, prevention, and treatment of diseases, particularly cancer.
Prenetics' consumer initiatives are spearheaded by IM8, a health and wellness brand. Another key offering is CircleDNA, which utilizes next-generation sequencing technology to provide comprehensive DNA testing for consumers, offering insights into health, wellness, and genetic predispositions.
The company's clinical arm includes Insighta, a joint venture focused on developing multi-cancer early detection technologies. Additionally, ACT Genomics develops and provides a variety of genomic profiling panels, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests, tailored to meet specific clinical needs. ACTLiquid Pro, a sequencing-based liquid biopsy assay, and ACTMonitor, which tracks drug resistance, treatment response, and cancer recurrence in real-time, are among its notable products. ACT Risk offers management solutions for assessing and mitigating cancer risks. Wikipedia
Founded
2014
Website
Employees
322